Bristol Myers Squibb Company $BMY Stock Holdings Increased by King Luther Capital Management Corp

Posted by Francis Steltz on Nov 12th, 2026

King Luther Capital Management Corp raised its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 1.7% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 606,134 shares of the biopharmaceutical company’s stock after purchasing an additional 9,890 shares during the period. King Luther Capital Management Corp’s holdings in Bristol Myers Squibb were worth $37,823,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Lazard Asset Management LLC raised its holdings in Bristol Myers Squibb by 23.7% in the 1st quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company’s stock worth $116,693,000 after acquiring an additional 368,193 shares during the last quarter. Callan Family Office LLC bought a new position in Bristol Myers Squibb in the 2nd quarter valued at approximately $3,575,000. Saudi Central Bank lifted its position in Bristol Myers Squibb by 90.2% in the 2nd quarter. Saudi Central Bank now owns 142,922 shares of the biopharmaceutical company’s stock valued at $8,235,000 after acquiring an additional 67,780 shares in the last quarter. BlackRock Inc. boosted its stake in Bristol Myers Squibb by 5.1% during the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after purchasing an additional 8,702,106 shares during the last quarter. Finally, Envestnet Asset Management Inc. boosted its stake in Bristol Myers Squibb by 17.4% during the 2nd quarter. Envestnet Asset Management Inc. now owns 2,142,754 shares of the biopharmaceutical company’s stock valued at $123,465,000 after purchasing an additional 317,360 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on BMY shares. HSBC reissued a “hold” rating and issued a $65.00 target price (up from $60.00) on shares of Bristol Myers Squibb in a report on Thursday, September 10th. JPMorgan Chase & Co. boosted their target price on Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. The Goldman Sachs Group upgraded shares of Bristol Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 16th. Guggenheim reaffirmed a “buy” rating and set a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Finally, Jefferies Financial Group reissued a “buy” rating and set a $76.00 price objective on shares of Bristol Myers Squibb in a report on Monday, October 12th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $65.46.

Get Our Latest Stock Report on Bristol Myers Squibb

Bristol Myers Squibb Stock Up 0.2%

BMY opened at $62.91 on Thursday. The company has a current ratio of 1.59, a quick ratio of 1.44 and a debt-to-equity ratio of 1.79. Bristol Myers Squibb Company has a 1-year low of $45.26 and a 1-year high of $68.64. The company has a market capitalization of $128.59 billion, a PE ratio of 13.95, a PEG ratio of 0.32 and a beta of 0.20. The firm’s 50 day simple moving average is $62.09 and its two-hundred day simple moving average is $60.23.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.25. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 60.48%. The business had revenue of $13.07 billion for the quarter, compared to analysts’ expectations of $12.72 billion. During the same quarter last year, the company posted $1.63 EPS. The company’s revenue was up 6.9% compared to the same quarter last year. As a group, equities analysts forecast that Bristol Myers Squibb Company will post 6.45 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, November 2nd. Investors of record on Friday, October 2nd were issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.0%. The ex-dividend date of this dividend was Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.88%.

Insider Buying and Selling at Bristol Myers Squibb

In other Bristol Myers Squibb news, Director Julia A. Haller sold 3,800 shares of the company’s stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $63.31, for a total value of $240,578.00. Following the completion of the sale, the director owned 30,279 shares in the company, valued at $1,916,963.49. This represents a 11.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the transaction, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. This trade represents a 2.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.05% of the stock is currently owned by insiders.

About Bristol Myers Squibb

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.